Recursion Pharmaceuticals (NasdaqGS:RXRX) reports its first AI enabled clinical proof of concept in familial adenomatous polyposis. The company advances five clinical programs, signaling broader use ...

Recursion Pharmaceuticals (RXRX) is back in focus after reporting fourth quarter and full year 2025 results, highlighting much higher quarterly revenue, a smaller net loss, and fresh commentary on its ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the 11 most popular AI penny stocks to buy now. On February 25, Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) reported Q4 revenue of $35.5 million ...

Recursion Pharmaceuticals, Inc ( (RXRX)) has held its Q4 earnings call. Read on for the main highlights of the call.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the Low Risk Penny Stocks to Buy Now. On February 27, Bank of America ...

Logan Graham, the leader of the red team, recalled the bioweapons scare as an example of the challenges Anthropic faces at a pivotal moment for the company and the world. Anthropic is the frontier AI ...

Today is Microsoft's March 2026 Patch Tuesday with security updates for 79 flaws, including 2 publicly disclosed zero-day ...

By Joseph Tulloch For years, AI safety experts have been warning of a future moment where AI models become advanced enough to ...

Artificial intelligence is rapidly inventing new drugs for diseases from Parkinson's disease and antibiotic-resistant superbugs to rare lung conditions.

We are approaching the integration of artificial intelligence into our universities in a piecemeal rather than a comprehensive fashion.

This edition of Market Factors starts with an extremely bullish strategist from HSBC who believes most of the bad market news is behind us. We move on to takeaways from a recent technology lovefest in ...

I worry that at the time when they should be developing their own voices, they’re being told they don’t need to bother. AI writes for us, reads for us, thinks for us. It replaces our voice with its ...